Bruker Corp (BRKR)
53.13
-1.36
(-2.50%)
USD |
NASDAQ |
Nov 15, 09:47
Bruker Cash from Financing (Quarterly): -2.70M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -2.70M |
| June 30, 2024 | 1.156B |
| March 31, 2024 | 151.70M |
| December 31, 2023 | -59.90M |
| September 30, 2023 | -92.50M |
| June 30, 2023 | -10.30M |
| March 31, 2023 | -30.70M |
| December 31, 2022 | -36.10M |
| September 30, 2022 | -82.00M |
| June 30, 2022 | -79.80M |
| March 31, 2022 | -217.40M |
| December 31, 2021 | 404.30M |
| September 30, 2021 | -2.60M |
| June 30, 2021 | -44.90M |
| March 31, 2021 | -38.10M |
| December 31, 2020 | -74.30M |
| September 30, 2020 | -225.50M |
| June 30, 2020 | -53.10M |
| March 31, 2020 | 191.30M |
| December 31, 2019 | 277.90M |
| September 30, 2019 | -19.50M |
| June 30, 2019 | 50.40M |
| March 31, 2019 | -8.80M |
| December 31, 2018 | 76.60M |
| September 30, 2018 | 14.60M |
| Date | Value |
|---|---|
| June 30, 2018 | -4.80M |
| March 31, 2018 | -198.80M |
| December 31, 2017 | -89.50M |
| September 30, 2017 | -38.90M |
| June 30, 2017 | 1.70M |
| March 31, 2017 | -32.30M |
| December 31, 2016 | 26.10M |
| September 30, 2016 | -10.50M |
| June 30, 2016 | -2.00M |
| March 31, 2016 | -41.50M |
| December 31, 2015 | -168.20M |
| September 30, 2015 | -0.10M |
| June 30, 2015 | -5.20M |
| March 31, 2015 | 4.10M |
| December 31, 2014 | 0.50M |
| September 30, 2014 | 3.00M |
| June 30, 2014 | 0.70M |
| March 31, 2014 | 2.50M |
| December 31, 2013 | 1.70M |
| September 30, 2013 | 22.10M |
| June 30, 2013 | 2.40M |
| March 31, 2013 | 0.30M |
| December 31, 2012 | 1.20M |
| September 30, 2012 | 15.70M |
| June 30, 2012 | 2.70M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-225.50M
Minimum
Sep 2020
1.156B
Maximum
Jun 2024
56.56M
Average
-37.10M
Median
Cash from Financing (Quarterly) Benchmarks
| Azenta Inc | -224.44M |
| Harvard Bioscience Inc | 2.104M |
| Bionano Genomics Inc | -1.978M |
| Akoya Biosciences Inc | -2.125M |
| Singular Genomics Systems Inc | 0.08M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 38.40M |
| Cash from Investing (Quarterly) | -67.60M |
| Free Cash Flow | 156.70M |
| Free Cash Flow Per Share (Quarterly) | 0.0382 |
| Free Cash Flow to Equity (Quarterly) | -133.10M |
| Free Cash Flow to Firm (Quarterly) | 12.61M |
| Free Cash Flow Yield | 1.99% |